Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > ACADEMIA
ACADEMIA
- 5-Year Cancer Survival Rates in Japan Stand at 66.1%: NCC
August 9, 2019
- NCC Hospital Crafting Scheme to Offer Off-Label Meds after Genomic Profiling
July 23, 2019
- Submission of Oncolytic Virus G47Δ Lagging as Team Still Preps for Manufacturing
July 22, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- Japanese Data More Positive for Keytruda’s Frontline Use in Gastric Cancer
July 22, 2019
- Keytruda Shows Promise in Japanese HCC Patients despite Global Miss
July 22, 2019
- Keytruda Slashes Death Risk by 78% in Japanese Head and Neck Cancer Patients
July 19, 2019
- New Pancreatic Cancer Guidelines Recommend FOLFIRINOX as 1st-Line Therapy
July 19, 2019
- TMDU, Tokyo Govt Join Hands for Open Innovation in Drug Discovery, Healthcare
July 18, 2019
- Virologist Expresses Concern over Spread of Resistant Flu Viruses to Xofluza
July 17, 2019
- Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
- NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
- Gynecologist Stresses Urgent Need to Resume HPV Vaccinations, Cites Age Disparity in Cervical Cancer Risk
July 10, 2019
- Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
- Univ. of Tokyo, 3H to Start Matching Program for Rare Disease R&D
May 21, 2019
- Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
May 17, 2019
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…